MicroRNA-6838-5p suppresses metastasis and increases cisplatin sensitivity in lung cancer

Abstract

Cisplatin (DDP) chemotherapy is effective to treat tumors but potentially limited to drug resistance. The research studied miR-6838-5p in controlling LC cells’ DDP resistance. First, clinical samples of DDP-resistant LC and DDP-sensitive LC were obtained and clinicopathological information was analyzed. Then, a DDP-resistant cell model (A549/DDP) was established and transfected with the plasmid vector that interfered with the expression of miR-6838-5p or SYPL1. Cell viability and half-maximal inhibitory concentration (IC50), apoptosis, migration and invasion were detected by CCK-8, flow cytometry, and Transwell, respectively. miR-6838-5p, SYPL1, MMP-2 and MMP-9 expression was determined by RT-qPCR or immunoblot analysis. Finally, the targeting relationship between miR-6838-5p and SYPL1 was verified by bioinformatics website and luciferase reporter assay. Experiment result showed that reduced miR-6838-5p and upregulated SYPL1 were presented in DDP-resistant LC. Elevating miR-6838-5p or suppressing SYPL1 repressed proliferative, migratory, and invasive activities and DDP resistance, but promoted apoptosis in A549/DDP cells. MiR-6838-5p targeted SYPL1. Moreover, SYPL1 overexpression turned around elevated miR-6838-5p-mediated effect on A549/DDP metastasis and DDP resistance. In conclusion, miR-6838-5p targets SYPL1 to restrain metastasis and DDP resistance of LC cells.